Evidence map›Paper›PMID 27126515›Full record

ArticleMolecules and cells2016

Magnaporthe oryzae Effector AVR-Pii Helps to Establish Compatibility by Inhibition of the Rice NADP-Malic Enzyme Resulting in Disruption of Oxidative Burst and Host Innate Immunity.

Raksha Singh, Sarmina Dangol, Yafei Chen, Jihyun Choi, Yoon-Seong Cho, Jea-Eun Lee, Mi-Ok Choi, Nam-Soo Jwa

Open access · diamondAbstract read
In one paragraph

Article in Molecules and cells, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
11.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 101 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Current issues in molecular biology · 2026
    Article
  6. Article
  7. Ferroptosis in plant immunity.Plant communications · 2025
    Review
  8. Review
  9. Differential gene expression in ripe mango fruit (Frontiers in fungal biology · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Pyricularia oryzae: Lab star and field scourge.Molecular plant pathology · 2024
    Review
  14. Article
  15. Article
  16. Cytoplasmic CaFrontiers in plant science · 2024
    Article
  17. The roles ofFrontiers in plant science · 2024
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Raksha SinghDivision of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 143-747, Korea.
Sarmina DangolDivision of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 143-747, Korea.
Yafei ChenDivision of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 143-747, Korea.
Jihyun ChoiDivision of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 143-747, Korea.
Yoon-Seong ChoDivision of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 143-747, Korea.
Jea-Eun LeeDivision of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 143-747, Korea.
Mi-Ok ChoiDivision of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 143-747, Korea.
Nam-Soo JwaDivision of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 143-747, Korea.
Sejong University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plant disease resistance occurs as a hypersensitive response (HR) at the site of attempted pathogen invasion. This specific event is initiated in response to recognition of pathogen-associated molecular pattern (PAMP) and subsequent PAMP-triggered immunity (PTI) and effector-triggered immunity (ETI). Both PTI and ETI mechanisms are tightly connected with reactive oxygen species (ROS) production and disease resistance that involves distinct biphasic ROS production as one of its pivotal plant immune responses. This unique oxidative burst is strongly dependent on the resistant cultivars because a monophasic ROS burst is a hallmark of the susceptible cultivars. However, the cause of the differential ROS burst remains unknown. In the study here, we revealed the plausible underlying mechanism of the differential ROS burst through functional understanding of the Magnaporthe oryzae (M. oryzae) AVR effector, AVR-Pii. We performed yeast two-hybrid (Y2H) screening using AVR-Pii as bait and isolated rice NADP-malic enzyme2 (Os-NADP-ME2) as the rice target protein. To our surprise, deletion of the rice Os-NADP-ME2 gene in a resistant rice cultivar disrupted innate immunity against the rice blast fungus. Malic enzyme activity and inhibition studies demonstrated that AVR-Pii proteins specifically inhibit in vitro NADP-ME activity. Overall, we demonstrate that rice blast fungus, M. oryzae attenuates the host ROS burst via AVR-Pii-mediated inhibition of Os-NADP-ME2, which is indispensable in ROS metabolism for the innate immunity of rice. This characterization of the regulation of the host oxidative burst will help to elucidate how the products of AVR genes function associated with virulence of the pathogen.

Indexed as

Disease ResistanceFungal ProteinsGene Expression Regulation, PlantHost-Pathogen InteractionsImmunity, InnateMagnaportheMalate DehydrogenaseMutagenesis, Site-DirectedOryzaPlant DiseasesPlant ProteinsReactive Oxygen SpeciesFungal ProteinsMalate Dehydrogenasemalate dehydrogenase (oxaloacetate-decarboxylating) (NADP+)Plant ProteinsReactive Oxygen SpeciesAVR-effectorsgene-for-gene interactionNADP-Malic enzymereactive oxygen speciesrice

Identifiers

PMID27126515
PMCPMC4870191
OpenAlexW2411580214

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.